CNS Pharmaceuticals Appoints Rami Levin as New CEO Starting January 2026

CNS Pharmaceuticals has announced the appointment of Rami Levin as its new Chief Executive Officer, effective January 1, 2026. Levin takes over from John Climaco, who has led the company through significant developments in the biopharmaceutical sector. This leadership transition comes as CNS Pharmaceuticals continues to focus on advancing its innovative therapies for cancer treatment.

Levin brings a wealth of experience to CNS, having previously served as president and CEO of Saniona, where he successfully oversaw strategic initiatives that propelled the company’s growth. His background also includes a tenure as CEO of ImStem Biotechnology, a role that further honed his leadership skills in the biotechnology industry.

CNS Pharmaceuticals, headquartered in Houston, Texas, is renowned for its commitment to developing novel therapies targeting rare and orphan diseases. The company is currently advancing its lead product candidate, Berubicin, which is under investigation for the treatment of recurrent glioblastoma, an aggressive form of brain cancer.

In a statement regarding his new role, Levin expressed excitement about joining CNS Pharmaceuticals at such a pivotal moment. He emphasized the company’s potential to make a significant impact in oncology, stating, “I am thrilled to lead CNS Pharmaceuticals as we continue to navigate the complex landscape of drug development and strive to bring transformative therapies to patients in need.”

The appointment of Levin marks a new chapter for CNS Pharmaceuticals, aiming to build on the foundation established by Climaco. Under Climaco’s leadership, the company made substantial strides in both research and partnerships, enhancing its visibility in the competitive biopharmaceutical market.

As the company prepares for this transition, industry analysts are closely monitoring CNS Pharmaceuticals’ next steps. With Levin at the helm, stakeholders are optimistic about the strategic direction the company will take, particularly in its ongoing clinical trials and collaborations.

Investors and partners alike will be watching how Levin’s previous experience will influence CNS Pharmaceuticals’ operational strategies and growth trajectory in the coming years.